

REMARKS


Claims 4, 8, 9, 17-19 have been amended, claims 14, 16, 20-24, and 26-31 have been canceled, and new claims 32-38 have been added. The dependency of claims 4, 8, 9, 17, and 18 has been amended. Claim 17 has also been amended to recite “a pharmaceutically acceptable medium.” This amendment finds support, for example, in original claim 25. New claim 32 finds support, for example, in original claims 1, 2, and 17, and page 20, lines 13-15, of the English language specification. New claim 33 finds support, for example, in original claim 9, new claim 34 finds support, for example, in original claims 10 and 18, new claim 35 finds support, for example, in original claims 12 and 27, new claim 36 finds support, for example, in original claim 14, new claim 37 finds support, for example, in original claims 3 and 6, and new claim 38 finds support, for example, in original claims 4, 23, and 30. No new matter has been added by the present amendment.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 2 November 2007



James D. DeCamp, Ph.D.

Reg. No. 43,580

*JAN N. TITTEL, Ph.D.
Reg. No. 53,290*

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045